Hormone therapy for locally advanced prostate cancer

Journal of Urology

Volumn 168, Issue 2, 2002, Pages 546-549

  Fowler Jr , Jackson E ^a,b   Bigler, Steven A ^a,b   White, Paige C ^a,b   Duncan, William L ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Androgen antagonists; Comorbidity; Prostate; Prostatic neoplasms; Survival

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; COMORBIDITY; FOLLOW UP; HEMATURIA; HIP FRACTURE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETER OBSTRUCTION;

EID: 0036079425     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64676-9     Document Type: Article

References (22)

1. Race and cause specific survival with prostate cancer: Influence of clinical stage, Gleason score, age and treatment
2. Early results of a prospective study of hormone therapy for patients with locally advanced prostate cancer
3. The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer
4. The role of neoadjuvant hormonal manipulation in localized prostatic cancer
5. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group
6. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
7. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
8. Classification of prostatic carcinomas
9. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
10. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy
11. Long-term survival among men with conservatively treated localized prostate cancer
12. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)
13. Flutamide hepatotoxicity
14. Does neoadjuvant hormone treatment compromise subsequent androgen suppression in prostate cancer patients who fail initial radiation therapy: A secondary analysis of RTOG 86-10
15. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
16. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control
17. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era
18. Competing risk analysis of men aged 55 to 74 at diagnosis managed conservatively for clinically localized prostate cancer
19. Osteoporosis after orchiectomy for prostate cancer
20. Epidemiology of osteoporosis and osteoporotic fractures